Cargando…

Automated high throughput microscale antibody purification workflows for accelerating antibody discovery

To rapidly find “best-in-class” antibody therapeutics, it has become essential to develop high throughput (HTP) processes that allow rapid assessment of antibodies for functional and molecular properties. Consequently, it is critical to have access to sufficient amounts of high quality antibody, to...

Descripción completa

Detalles Bibliográficos
Autores principales: Luan, Peng, Lee, Sophia, Arena, Tia A., Paluch, Maciej, Kansopon, Joe, Viajar, Sharon, Begum, Zahira, Chiang, Nancy, Nakamura, Gerald, Hass, Philip E., Wong, Athena W., Lazar, Greg A., Gill, Avinash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973699/
https://www.ncbi.nlm.nih.gov/pubmed/29494273
http://dx.doi.org/10.1080/19420862.2018.1445450
_version_ 1783326681828687872
author Luan, Peng
Lee, Sophia
Arena, Tia A.
Paluch, Maciej
Kansopon, Joe
Viajar, Sharon
Begum, Zahira
Chiang, Nancy
Nakamura, Gerald
Hass, Philip E.
Wong, Athena W.
Lazar, Greg A.
Gill, Avinash
author_facet Luan, Peng
Lee, Sophia
Arena, Tia A.
Paluch, Maciej
Kansopon, Joe
Viajar, Sharon
Begum, Zahira
Chiang, Nancy
Nakamura, Gerald
Hass, Philip E.
Wong, Athena W.
Lazar, Greg A.
Gill, Avinash
author_sort Luan, Peng
collection PubMed
description To rapidly find “best-in-class” antibody therapeutics, it has become essential to develop high throughput (HTP) processes that allow rapid assessment of antibodies for functional and molecular properties. Consequently, it is critical to have access to sufficient amounts of high quality antibody, to carry out accurate and quantitative characterization. We have developed automated workflows using liquid handling systems to conduct affinity-based purification either in batch or tip column mode. Here, we demonstrate the capability to purify >2000 antibodies per day from microscale (1 mL) cultures. Our optimized, automated process for human IgG1 purification using MabSelect SuRe resin achieves ∼70% recovery over a wide range of antibody loads, up to 500 µg. This HTP process works well for hybridoma-derived antibodies that can be purified by MabSelect SuRe resin. For rat IgG2a, which is often encountered in hybridoma cultures and is challenging to purify via an HTP process, we established automated purification with GammaBind Plus resin. Using these HTP purification processes, we can efficiently recover sufficient amounts of antibodies from mammalian transient or hybridoma cultures with quality comparable to conventional column purification.
format Online
Article
Text
id pubmed-5973699
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-59736992018-05-31 Automated high throughput microscale antibody purification workflows for accelerating antibody discovery Luan, Peng Lee, Sophia Arena, Tia A. Paluch, Maciej Kansopon, Joe Viajar, Sharon Begum, Zahira Chiang, Nancy Nakamura, Gerald Hass, Philip E. Wong, Athena W. Lazar, Greg A. Gill, Avinash MAbs Report To rapidly find “best-in-class” antibody therapeutics, it has become essential to develop high throughput (HTP) processes that allow rapid assessment of antibodies for functional and molecular properties. Consequently, it is critical to have access to sufficient amounts of high quality antibody, to carry out accurate and quantitative characterization. We have developed automated workflows using liquid handling systems to conduct affinity-based purification either in batch or tip column mode. Here, we demonstrate the capability to purify >2000 antibodies per day from microscale (1 mL) cultures. Our optimized, automated process for human IgG1 purification using MabSelect SuRe resin achieves ∼70% recovery over a wide range of antibody loads, up to 500 µg. This HTP process works well for hybridoma-derived antibodies that can be purified by MabSelect SuRe resin. For rat IgG2a, which is often encountered in hybridoma cultures and is challenging to purify via an HTP process, we established automated purification with GammaBind Plus resin. Using these HTP purification processes, we can efficiently recover sufficient amounts of antibodies from mammalian transient or hybridoma cultures with quality comparable to conventional column purification. Taylor & Francis 2018-03-29 /pmc/articles/PMC5973699/ /pubmed/29494273 http://dx.doi.org/10.1080/19420862.2018.1445450 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Report
Luan, Peng
Lee, Sophia
Arena, Tia A.
Paluch, Maciej
Kansopon, Joe
Viajar, Sharon
Begum, Zahira
Chiang, Nancy
Nakamura, Gerald
Hass, Philip E.
Wong, Athena W.
Lazar, Greg A.
Gill, Avinash
Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
title Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
title_full Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
title_fullStr Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
title_full_unstemmed Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
title_short Automated high throughput microscale antibody purification workflows for accelerating antibody discovery
title_sort automated high throughput microscale antibody purification workflows for accelerating antibody discovery
topic Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973699/
https://www.ncbi.nlm.nih.gov/pubmed/29494273
http://dx.doi.org/10.1080/19420862.2018.1445450
work_keys_str_mv AT luanpeng automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT leesophia automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT arenatiaa automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT paluchmaciej automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT kansoponjoe automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT viajarsharon automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT begumzahira automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT chiangnancy automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT nakamuragerald automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT hassphilipe automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT wongathenaw automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT lazargrega automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery
AT gillavinash automatedhighthroughputmicroscaleantibodypurificationworkflowsforacceleratingantibodydiscovery